BIOLASE, INC false 0000811240 0000811240 2021-06-11 2021-06-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2021

 

 

BIOLASE, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware
  001-36385
  87-0442441
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

27042 Towne Centre Dr., Suite 270

Foothill Ranch, CA

  92610
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule l4a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share    BIOL    The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 11, 2021, Biolase, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following are the results of the voting on the proposals submitted to stockholders at the Annual Meeting.

Proposal 1 – Stockholders elected each of the Company’s seven nominees for director, as set forth below:

 

Nominee

   For      Against      Abstain      Broker Non-Votes  

Richard B. Lanman, M.D.

     40,441,145        3,054,078        2,535,346        30,119,914  

Jonathan T. Lord, M.D.

     39,907,848        3,499,920        2,622,801        30,119,914  

Garret Sato

     40,068,029        3,355,032        2,607,508        30,119,914  

Elaine C. Wagner, M.D.

     40,808,062        3,303,595        1,918,912        30,119,914  

John R. Beaver

     40,429,354        3,307,209        2,294,006        30,119,914  

Jess Roper

     40,302,734        3,353,334        2,374,501        30,119,914  

Michael C. DiTolla D.D.S.

     40,211,554        3,199,982        2,619,033        30,119,914  

Proposal 2 – Stockholders voted, on an advisory basis, to approve the compensation of the Company’s named executive officers, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

36,449,027

  7,197,174   2,384,368   30,119,914

Proposal 3 – Stockholders voted to approve an amendment to the BIOLASE, Inc. 2018 Long-Term Incentive Plan (the “2018 Plan”), to increase the number of shares available under the 2018 Plan by an additional 24,700,000 shares, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

31,714,081

  13,310,520   1,005,968   30,119,914

Proposal 4 – A majority of the outstanding Stockholders of the Company did not approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of Company common stock, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

54,175,511

  20,865,381   1,109,591  

Proposal 5 – A majority of the outstanding Stockholders of the Company did not approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 180 million shares to 235 million shares, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

52,917,649

  22,109,529   1,123,305  

Proposal 6 – Stockholders ratified the appointment of BDO USA, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2021, as set forth below:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

67,998,059

  5,330,781   2,821,643  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 11, 2021     BIOLASE, INC.
    By:  

/s/ John R. Beaver

    Name:   John R. Beaver
    Title:   President and Chief Executive Officer
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Biolase Charts.
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Biolase Charts.